research Author response: Deletion of the MAD2L1 spindle assembly checkpoint gene is tolerated in mouse models of acute T-cell lymphoma and hepatocellular carcinoma
Deleting the MAD2L1 gene is tolerated in certain mouse cancer models.
Search
for
Sort by
Research
630-660 / 1000+ results
research Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
Baricitinib is an effective treatment for severe alopecia areata.
research Data from Spontaneous Squamous Cell Carcinoma Induced by the Somatic Inactivation of Retinoblastoma and Trp53 Tumor Suppressors
Loss of the p53 gene alone causes tumors, and losing both p53 and Rb genes speeds up aggressive skin cancer.
research Association of Janus kinase inhibitors with reduced depression in alopecia areata
JAK inhibitors may reduce depression in people with alopecia areata.
research JAK inhibitors and alopecia areata
JAK inhibitors help regrow hair in alopecia areata patients, improving their quality of life.
research Oral Combination Treatment of Gefitinib (IressaTM) and Sasam-Kyeongokgo: Synergistic Effects on the NCI-H520 Tumor Cell Line
Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.
research A Case of Cicatricial Alopecia Associated with Erlotinib
Erlotinib can cause hair loss as a side effect.
research The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study
Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
research Exploring novel management options for alopecia areata
JAK inhibitors can help treat alopecia areata but have risks and high costs.
research Hair loss and Hedgehog inhibitors: a class effect?
Hedgehog pathway inhibitors used for skin cancer can cause significant hair loss, which may improve after stopping the medication.
research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
Upadacitinib improved multiple immune-related conditions in one patient.
research 329 Mechanisms of Cutaneous Adverse Events during Targeted Cancer Therapy
Targeted cancer therapies can cause skin side effects, but activating SOS in the skin may help reduce them.
research Protein Kinase C Epsilon Signals Ultraviolet Light‐induced Cutaneous Damage and Development of Squamous Cell Carcinoma Possibly Through Induction of Specific Cytokines in a Paracrine Mechanism¶
Protein kinase C epsilon may promote skin cancer development after UV exposure by affecting nearby cells.
research Supplementary Figures, Tables and Legends from Mobilizing Transit-Amplifying Cell-Derived Ectopic Progenitors Prevents Hair Loss from Chemotherapy or Radiation Therapy
Boosting certain cell signals can prevent hair loss from chemotherapy and radiation.
research Slow progress in prostate cancer
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
research Síndrome PRIDE: una práctica forma de identificar los efectos adversos cutáneos de los inhibidores del EGFR
PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.
research Comparison of Efficacy and Specificity in Cancer‐Targeting Prodrug Conjugates
The document concludes that biotin, folate, and RGD peptides are promising for targeting cancer cells with prodrugs, but the conjugates are not yet tested for use.
research Small Molecule Inhibitors and Inflammatory Skin Diseases
New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.
research Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
research A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA): Final study results
Topical calcitriol (BPM31543) is safe for preventing hair loss from chemotherapy and shows some effectiveness.
research Short-term malignancy risk of JAK inhibitors in severe alopecia areata: a multicenter cohort study
JAK inhibitors do not increase cancer risk in severe alopecia areata compared to traditional treatments.
research Emerging drugs and combination strategies for basal cell carcinoma
New treatments for a type of skin cancer show promise but have side effects and may work better with other therapies.
research 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
research JAK inhibitors for the treatment of alopecia areata
JAK inhibitors show promise in treating moderate to severe alopecia areata.
research ICP5249 Promotes Hair Growth by Activating the AMPK-Autophagy Signaling Pathway
ICP5249 helps hair grow by activating a specific cell pathway.
research Epidermal growth factor receptor mutant T790M-L858R-V948R inhibitor from Calophyllum inophyllum L. leaf as potential non-small cell lung cancer drugs
A compound from Calophyllum inophyllum L. leaf may help treat non-small cell lung cancer.
research Upadacitinib for the management of severe alopecia areata in adolescent patients: a single-centre retrospective study
Upadacitinib is effective and safe for treating severe alopecia areata in teens.
research Abstract P5-11-11: A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA)
Topical calcitriol appears safe and may reduce hair loss during chemotherapy.
research Overcoming genetic drivers in alopecia areata: hair regrowth in a patient with AIRE gene mutation (autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy, APECED syndrome) treated with ruxolitinib
Ruxolitinib helped a patient with alopecia areata regrow hair.
research Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment
EGFR inhibitors in breast cancer treatment can cause serious skin issues affecting patient quality of life.